Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI   US72940R1023

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
2.86(c) 3.015(c) 2.91(c) 2.86(c) 2.83(c) Last
117 823 228 853 115 612 117 536 37 834 Volume
+2.14% +5.42% -3.48% -1.72% -1.05% Change
More quotes
Financials ($)
Sales 2015 0,52 M
EBIT 2015 -25,2 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 15,3 M
EBIT 2016 -26,9 M
Net income 2016 -27,3 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 381x
Capi. / Sales 2016 13,0x
Capitalization 200 M
More Financials
Company
Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases.The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
03/25 PLURISTEM THERAPEUTICS : kündigt wichtige strategische Ziele für die Entwicklung..
03/24 PLURISTEM THERAPEUTICS : Regulation FD Disclosure, Financial Statements and Exhi..
03/24 PLURISTEM THERAPEUTICS : Announces Key Strategic Objectives for Development of P..
03/24 PLURISTEM THERAPEUTICS : Announces Key Strategic Objectives for Development of P..
03/24 Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in He..
03/10 PLURISTEM THERAPEUTICS : to Present Data at Regenerative Medicine Conferences in..
03/09 Pluristem to Present Data at Regenerative Medicine Conferences in Japan and S..
03/05 PLURISTEM THERAPEUTICS : and Hadassah Medical Center Announce Significant Data S..
More news
Sector news : Biotechnology & Medical Research - NEC
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/24 Pluristem details development plan for second cell product
02/17 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/12 NEOSTEM : The Levi Strauss Of Cell Therapy
02/11 German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cel..
02/06 SEEKING ALPHA'S BIOTECH WEEKLY : Questioning Gilead, MannKind To Market, And Mor..


Comments 
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF